<DOC>
	<DOCNO>NCT02973724</DOCNO>
	<brief_summary>The investigator design study investigate remifentanil effect-site concentration 95 % patient ( EC95 ) prevent cough laryngomicrosurgery propofol anesthesia .</brief_summary>
	<brief_title>EC95 Remifentanil Preventing Cough</brief_title>
	<detailed_description>At end surgery , propofol infusion stop remifentanil titrate predetermine ( initial concentration 1.0 ng/ml first patient ) . Extubation perform patient open eyes spontaneous respiration adequate tidal volume ventilatory frequency confirm .</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>ASA III patient undergo general anesthesia laryngomicrosurgery Anticipated difficult airway COPD , Asthma Recent URI ( &lt; 2 week ) Severe cardiac , hepatic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Extubation</keyword>
	<keyword>Remifentanil</keyword>
	<keyword>Laryngomicrosurgery</keyword>
</DOC>